Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 14 studies | 33% ± 12% | |
epithelial cell | 4 studies | 35% ± 19% | |
fibroblast | 4 studies | 18% ± 2% | |
type II pneumocyte | 4 studies | 23% ± 10% | |
glutamatergic neuron | 4 studies | 24% ± 6% | |
endothelial cell | 3 studies | 20% ± 4% | |
GABAergic neuron | 3 studies | 23% ± 2% | |
abnormal cell | 3 studies | 21% ± 4% | |
oligodendrocyte precursor cell | 3 studies | 21% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 32% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2843.37 | 245 / 245 | 100% | 75.82 | 502 / 502 |
intestine | 100% | 2537.73 | 966 / 966 | 100% | 89.16 | 525 / 527 |
lung | 100% | 4696.84 | 576 / 578 | 100% | 91.81 | 1152 / 1155 |
brain | 100% | 3930.17 | 2636 / 2642 | 100% | 77.31 | 702 / 705 |
esophagus | 100% | 2112.62 | 1443 / 1445 | 99% | 65.21 | 182 / 183 |
stomach | 100% | 2681.86 | 359 / 359 | 99% | 93.51 | 284 / 286 |
breast | 100% | 4260.48 | 459 / 459 | 99% | 59.71 | 1110 / 1118 |
ovary | 100% | 1794.62 | 180 / 180 | 99% | 47.73 | 426 / 430 |
liver | 100% | 3610.52 | 226 / 226 | 99% | 53.04 | 402 / 406 |
kidney | 100% | 3197.10 | 89 / 89 | 99% | 55.29 | 889 / 901 |
bladder | 100% | 2502.86 | 21 / 21 | 98% | 60.26 | 496 / 504 |
pancreas | 100% | 2145.89 | 328 / 328 | 98% | 43.21 | 174 / 178 |
uterus | 100% | 1802.34 | 170 / 170 | 97% | 36.26 | 443 / 459 |
skin | 100% | 5388.49 | 1809 / 1809 | 96% | 34.04 | 452 / 472 |
thymus | 100% | 2063.94 | 650 / 653 | 85% | 22.82 | 512 / 605 |
adrenal gland | 100% | 2047.91 | 257 / 258 | 83% | 20.30 | 191 / 230 |
adipose | 100% | 4536.82 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 33.32 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.82 | 1 / 1 |
blood vessel | 99% | 1844.87 | 1317 / 1335 | 0% | 0 | 0 / 0 |
heart | 95% | 1579.22 | 818 / 861 | 0% | 0 | 0 / 0 |
muscle | 90% | 1272.93 | 721 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 23.82 | 39 / 45 |
spleen | 63% | 522.92 | 153 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 21% | 3.43 | 6 / 29 |
peripheral blood | 19% | 254.05 | 180 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0141111 | Biological process | positive regulation of cGAS/STING signaling pathway |
GO_0018345 | Biological process | protein palmitoylation |
GO_0018230 | Biological process | peptidyl-L-cysteine S-palmitoylation |
GO_0006612 | Biological process | protein targeting to membrane |
GO_0044794 | Biological process | positive regulation by host of viral process |
GO_0000165 | Biological process | MAPK cascade |
GO_0033116 | Cellular component | endoplasmic reticulum-Golgi intermediate compartment membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0002178 | Cellular component | palmitoyltransferase complex |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0016409 | Molecular function | palmitoyltransferase activity |
GO_0019706 | Molecular function | protein-cysteine S-palmitoyltransferase activity |
GO_0043849 | Molecular function | Ras palmitoyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ZDHHC9 |
Protein name | Palmitoyltransferase ZDHHC9 (EC 2.3.1.225) (Zinc finger DHHC domain-containing protein 9) (DHHC-9) (DHHC9) (Zinc finger protein 379) (Zinc finger protein 380) Palmitoyltransferase (EC 2.3.1.225) |
Synonyms | ZNF379 CXorf11 UNQ261/PRO298 CGI-89 ZDHHC10 ZNF380 |
Description | FUNCTION: Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates, such as ADRB2, HRAS, NRAS and CGAS . The ZDHHC9-GOLGA7 complex is a palmitoyltransferase specific for HRAS and NRAS . May have a palmitoyltransferase activity toward the beta-2 adrenergic receptor/ADRB2 and therefore regulate G protein-coupled receptor signaling . Acts as a regulator of innate immunity by catalyzing palmitoylation of CGAS, thereby promoting CGAS homodimerization and cyclic GMP-AMP synthase activity . .; FUNCTION: (Microbial infection) Through a sequential action with ZDHHC20, rapidly and efficiently palmitoylates SARS coronavirus-2/SARS-CoV-2 spike protein following its synthesis in the endoplasmic reticulum (ER). In the infected cell, promotes spike biogenesis by protecting it from premature ER degradation, increases half-life and controls the lipid organization of its immediate membrane environment. Once the virus has formed, spike palmitoylation controls fusion with the target cell. . |
Accessions | Q5JYE8 ENST00000357166.11 ENST00000433917.5 H0Y6K6 ENST00000371064.7 Q9Y397 ENST00000406492.2 |